Geode Capital Management LLC boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 5.8% during the first quarter, Holdings Channel reports. The institutional investor owned 136,521 shares of the biopharmaceutical company’s stock after buying an additional 7,437 shares during the period. Geode Capital Management LLC’s holdings in Esperion Therapeutics were worth $4,820,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the first quarter valued at approximately $158,000. C WorldWide Group Holding A S purchased a new stake in Esperion Therapeutics during the first quarter valued at approximately $162,000. Princeton Alpha Management LP purchased a new stake in Esperion Therapeutics during the first quarter valued at approximately $205,000. Bank of Montreal Can raised its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares in the last quarter. Finally, American International Group Inc. raised its stake in Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 584 shares in the last quarter. Institutional investors own 85.39% of the company’s stock.

Shares of Esperion Therapeutics, Inc. (ESPR) traded up 1.95% during midday trading on Monday, hitting $50.29. 133,851 shares of the company’s stock were exchanged. The firm’s market cap is $1.14 billion. The stock’s 50-day moving average price is $47.09 and its 200 day moving average price is $35.27. Esperion Therapeutics, Inc. has a one year low of $9.40 and a one year high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the business earned ($0.62) EPS. Equities research analysts forecast that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/geode-capital-management-llc-has-4-82-million-position-in-esperion-therapeutics-inc-nasdaqespr/1486839.html.

Several analysts recently commented on the stock. UBS AG restated a “buy” rating and set a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Bank of America Corporation reaffirmed a “neutral” rating and set a $60.00 price objective on shares of Esperion Therapeutics in a report on Friday. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. Finally, Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $42.51.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.